Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-0810 vs Fulvestrant in Advanced ER+/HER2- Breast Cancer
NCT02569801Phase 2Terminated
- Sponsor
- Genentech
- Start
- Dec 2015
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of brilanestrant in breast cancer, sponsored by Genentech. Started Dec 2015; status: terminated.
02
Drugs
brilanestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02569801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02569801.